Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.
作者信息
Morrison Austin R, Johnson Joseph M, Ramesh Mayur, Bradley Patrick, Jennings Jeffery, Smith Zachary R
机构信息
Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan.
Department of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan.
出版信息
J Med Virol. 2020 Oct;92(10):1791-1792. doi: 10.1002/jmv.25907. Epub 2020 Jun 3.
Abstract
摘要
相似文献
1
Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.接受托珠单抗治疗的COVID-19患者的急性高甘油三酯血症
J Med Virol. 2020 Oct;92(10):1791-1792. doi: 10.1002/jmv.25907. Epub 2020 Jun 3.
2
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.托珠单抗在一名重症 COVID-19 患者中引起的急性高甘油三酯血症
Intern Med. 2020 Nov 15;59(22):2945-2949. doi: 10.2169/internalmedicine.5244-20. Epub 2020 Sep 19.
3
Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.托珠单抗治疗新型冠状病毒肺炎移植受者后的白细胞介素6水平
Kidney Int. 2020 Oct;98(4):1054. doi: 10.1016/j.kint.2020.06.025. Epub 2020 Jul 8.
4
Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.托珠单抗治疗一名患有镰状细胞病和急性胸部综合征的儿童重症 COVID-19 后病情显著改善。
Am J Hematol. 2020 Aug;95(8):E192-E194. doi: 10.1002/ajh.25855. Epub 2020 May 16.
5
Tocilizumab for COVID-19: a real 'miracle drug'?托珠单抗治疗新冠肺炎：一种真正的“神药”？
Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.
6
New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.托珠单抗治疗新冠病毒病患者的新治疗机遇：白细胞介素-6受体抑制剂与颌骨坏死的可能关联
Oral Oncol. 2020 Jul;106:104659. doi: 10.1016/j.oraloncology.2020.104659. Epub 2020 Mar 21.
7
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
8
Tocilizumab in the treatment of a critical COVID-19 patient: a case report.托珠单抗治疗危重症 COVID-19 患者 1 例报告。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5783-5787. doi: 10.26355/eurrev_202005_21372.
9
First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19.首先，勿伤为先：警惕在新冠肺炎中使用托珠单抗。
Chest. 2020 Nov;158(5):2233. doi: 10.1016/j.chest.2020.06.052.
10
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
引用本文的文献
1
Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis.托珠单抗治疗甲状腺眼病的疗效和安全性：一项系统评价与Meta分析
J Endocrinol Invest. 2025 Apr 30. doi: 10.1007/s40618-025-02595-4.
2
COVID-19-associated hypertriglyceridemia and impact of treatment.新型冠状病毒肺炎相关的高甘油三酯血症及治疗影响
Front Med (Lausanne). 2024 Feb 21;11:1326156. doi: 10.3389/fmed.2024.1326156. eCollection 2024.
3
Pancreatic and Hepatic Injury in COVID-19: A Worse Prognosis in NAFLD Patients?COVID-19 中的胰腺和肝脏损伤：非酒精性脂肪性肝病患者的预后更差？
Biomedicines. 2024 Jan 26;12(2):283. doi: 10.3390/biomedicines12020283.
4
Risks associated with acute pancreatitis (AP) with diabetic ketoacidosis (DKA) in COVID-19 patients: a literature review.COVID-19患者中急性胰腺炎（AP）合并糖尿病酮症酸中毒（DKA）的相关风险：文献综述
J Diabetes Metab Disord. 2023 Apr 8;22(1):135-146. doi: 10.1007/s40200-023-01207-3. eCollection 2023 Jun.
5
Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients.住院COVID-19患者的药物性急性胰腺炎
Diagnostics (Basel). 2023 Apr 12;13(8):1398. doi: 10.3390/diagnostics13081398.
6
Severe COVID-19-Induced Hemophagocytic Lymphohistiocytosis.严重新型冠状病毒肺炎所致噬血细胞性淋巴组织细胞增生症
Cureus. 2023 Jan 20;15(1):e34022. doi: 10.7759/cureus.34022. eCollection 2023 Jan.
7
Unusual case of propofol-related infusion syndrome complicating severe COVID-19 ARDS.严重 COVID-19 急性呼吸窘迫综合征并发异丙酚相关性输注综合征的不寻常病例。
BMJ Case Rep. 2023 Feb 7;16(2):e249456. doi: 10.1136/bcr-2022-249456.
8
COVID-19 and the Pancreas: A Narrative Review.2019冠状病毒病与胰腺：一篇叙述性综述
Life (Basel). 2022 Aug 23;12(9):1292. doi: 10.3390/life12091292.
9
Safety profile of COVID-19 drugs in a real clinical setting.在真实临床环境中 COVID-19 药物的安全性概况。
Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28.
10
The immunology and immunotherapy for COVID-19.COVID-19 的免疫学和免疫疗法。
Expert Rev Mol Med. 2021 Dec 17;23:e24. doi: 10.1017/erm.2021.30.
本文引用的文献
1
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.2019年冠状病毒病的治疗：早期及新出现的治疗选择综述
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. eCollection 2020 Apr.
2
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19：单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
3
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.托珠单抗与依那西普治疗类风湿关节炎的心血管安全性：一项随机对照试验。
Arthritis Rheumatol. 2020 Jan;72(1):31-40. doi: 10.1002/art.41095.
4
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.美国食品和药物管理局批准概要：托西珠单抗治疗嵌合抗原受体 T 细胞引起的严重或危及生命的细胞因子释放综合征。
Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.
5
Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System.托珠单抗诱发的胰腺炎：病例报告及来自美国食品药品监督管理局不良事件报告系统的数据综述
J Clin Pharm Ther. 2016 Dec;41(6):718-721. doi: 10.1111/jcpt.12456. Epub 2016 Sep 27.
6
Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness.高甘油三酯血症：危重病患者中丙泊酚镇静的潜在副作用。
Intensive Care Med. 2012 Dec;38(12):1990-8. doi: 10.1007/s00134-012-2688-8. Epub 2012 Sep 28.
7
Drug safety assessment in clinical trials: methodological challenges and opportunities.临床试验中的药物安全性评估：方法学挑战与机遇。
Trials. 2012 Aug 20;13:138. doi: 10.1186/1745-6215-13-138.
8
Role of interleukin-6 signalling in glucose and lipid metabolism.白细胞介素-6信号通路在葡萄糖和脂质代谢中的作用。
Acta Physiol (Oxf). 2008 Jan;192(1):37-48. doi: 10.1111/j.1748-1716.2007.01779.x.
9
Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors.重症监护病房中丙泊酚相关的高甘油三酯血症和胰腺炎：频率及危险因素分析
Pharmacotherapy. 2005 Oct;25(10):1348-52. doi: 10.1592/phco.2005.25.10.1348.
10
Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs.使用咪达唑仑或丙泊酚对重症患者进行长时间镇静：对脱机及成本的影响。
Crit Care Med. 1997 Jan;25(1):33-40. doi: 10.1097/00003246-199701000-00009.
Zotero 插件